Yun Beom Sang
Overview
Explore the profile of Yun Beom Sang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
57
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim Y, Kim J, Kang B, Kim I, Kim H, Lee W, et al.
Cancer Res Treat
. 2024 May;
56(4):1231-1239.
PMID: 38810969
Purpose: Since 2020, atezolizumab plus bevacizumab (Ate/Bev) has been the standard first-line therapy for unresectable hepatocellular carcinoma (HCC), but long-term treatment studies are limited. This study evaluated the clinical characteristics...
2.
Sang Y, Lee C, Kim S, Lee B, Kang B, Kim C, et al.
J Clin Med
. 2024 Apr;
13(5).
PMID: 38592150
The coronavirus disease 2019 (COVID-19) pandemic has proven challenging to the management of patients with cancer, particularly those receiving systemic therapy. This study aimed to evaluate the impact of COVID-19...
3.
Song Y, Yang H, Kang B, Cheon J, Kim I, Kim H, et al.
Liver Cancer
. 2024 Feb;
13(1):89-98.
PMID: 38344445
Introduction: Atezolizumab and bevacizumab (Ate/Bev) combination has become the new first-line systemic therapy for unresectable hepatocellular carcinoma (HCC). Although several studies reported thyroid dysfunction after treatment with immune checkpoint inhibitors,...
4.
Kim Y, Yang H, Lee W, Cheon J, Sang Y, Kang B, et al.
J Cancer
. 2023 May;
14(6):935-942.
PMID: 37151396
Immune checkpoint inhibitor (ICI) became a standard treatment for advanced renal cell carcinoma (RCC). However, clinically valid biomarkers of therapeutic outcome are lacking. We investigated the role of interleukin-10 (IL-10)...
5.
Sang Y, Kim G, Hwang S, Kang H, Chon H
J Clin Transl Hepatol
. 2023 Mar;
11(3):747-750.
PMID: 36969903
We report a case of a patient with c- amplified hepatocellular carcinoma (HCC) who had a dramatic response to cabozantinib despite being refractory to four previous lines of systemic therapy....
6.
Sang Y, Yang H, Lee W, Lee S, Kim S, Cheon J, et al.
Cancers (Basel)
. 2022 Dec;
14(23).
PMID: 36497467
Renal cell carcinoma (RCC) is the most common type of kidney malignancy worldwide with Pembrolizumab and axitinib treatment (Pembro/Axi) amongst the most effective first-line immunotherapies for advanced RCC. However, it...
7.
Sang Y, Kim J, Kim C, Hong M, Kim H, Cho B, et al.
Front Oncol
. 2022 Mar;
12:811247.
PMID: 35311091
AXL, along with MER and TYRO3, is a receptor tyrosine kinase from the TAM family. Although AXL itself is not thought to be a potent oncogenic driver, overexpression of AXL...
8.
Cheon J, Lee C, Sang Y, Choi H, Kim M, Ji J, et al.
Ther Adv Med Oncol
. 2021 Aug;
13:17588359211035983.
PMID: 34394748
Background: A recent phase II trial reported prolonged survival in patients with advanced biliary tract cancer (BTC) following treatment with nab-paclitaxel plus gemcitabine-cisplatin (Gem/Cis/nab-P). We aimed to evaluate the clinical...